Lynparza Meets Primary Endpoint in Phase 3 Trial in HRR MutationSelected Metastatic CastrationResistant Prostate Cancer

Lynparza Meets Primary Endpoint in Phase 3 Trial in HRR Mutation-Selected Metastatic Castration-Resistant Prostate Cancer

10:06 EDT 8 Aug 2019 | Speciality Pharma Journal

WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive results from the Phase III PROfound trial of LYNPARZA 300 mg (two 150 mg tablets) twice daily in men with metastatic castration-resistant prostate cancer (mCRPC) who have a *homologous recombination repair gene mutation (HRRm) and have …

More From BioPortfolio on "Lynparza Meets Primary Endpoint in Phase 3 Trial in HRR Mutation-Selected Metastatic Castration-Resistant Prostate Cancer"